Table 2.
Treatment planned and actually received (n = 674): Univariate analysis
|
Therapeutic education |
|||
| No (n = 304) | Yes (n = 370) | P | |
| Duration of bitherapy (wk)1 | |||
| Planned | 27.7 ± 8.9 | 27.1 ± 8.2 | 0.49 |
| Actual | 28.4 ± 12.7 | 30.3 ± 14.2 | 0.25 |
| Premature discontinuation (< 20 wk) | 44/304 (15) | 41/370 (11) | 0.20 |
| Peginterferon weekly dose (μg/kg) | |||
| Planned | 1.35 ± 0.29 | 1.41 ± 0.22 | 0.01 |
| Actual at 3 mo2 | 1.31 ± 0.30 | 1.38 ± 0.25 | 0.006 |
| Actual at 6 mo2 | 1.18 ± 0.35 | 1.25 ± 0.31 | 0.02 |
| Ribavirin daily dose (mg) | |||
| Planned | 897 ± 147 | 906 ± 154 | 0.67 |
| Actual at 3 mo2 | 871 ± 166 | 885 ± 175 | 0.25 |
| Actual at 6 mo2 | 771 ± 201 | 803 ± 209 | 0.06 |
Data are expressed as mean ± SD, or proportions of patients.
1
Date of end of bitherapy minus date of inclusion;
2
Cumulated over the past 3 mo (AUC, investigator report).